Seniors Diagnosed with Atrial Fibrillation Join Innovative Research Study in Memphis and Tamarac

BOSTON — (BUSINESS WIRE) - A global research study is now available in Memphis, Tenn., for an investigational medication that may help patients with a history of atrial fibrillation (AFib) decrease their risk of stroke. The LILAC-TIMI 76 study from Anthos Therapeutics, offers a potential new option for Afib patients deemed unsuitable for currently available oral anticoagulants by their physicians.

Patients with AFib are known to have a four to five times higher risk of stroke than the general population. Anticoagulant treatments are regularly prescribed by physicians and proven to effectively reduce the incidence of strokes. However, data from multiple registries and claims-based data analyses have shown that anywhere from 40% to 60% of AFib patients are not being optimally treated today. This is especially true in older adults, those with kidney or liver disease, those needing concomitant antiplatelet therapy, and patients with other factors associated with an increased risk of bleeding.

The LILAC-TIMI 76 phase 3 study is currently enrolling for patients to evaluate the efficacy and safety of abelacimab in high-risk patients with AFib deemed unsuitable for current anticoagulants by their physicians. Abelacimab is a dual-acting Factor XI inhibitor that may offer a safer treatment option. By doing so, the hope is that the current treatment gap is closed so that more eligible patients can get the treatment they deserve.

“Atrial fibrillation is a common issue in older adults and significantly impacts our seniors here in Memphis,” said Dr. Joseph Weinstein, Principal Investigator at Care Access - Memphis. “Our community being a part of this far-reaching international study is an exciting opportunity.”

This investigational research study is currently enrolling for adults ages 65+ with AFib, at high risk of stroke, and currently not taking certain oral anticoagulants or having stopped taking them within the last three months. To learn more, visit careaccess.com/studies or contact Care Access at (351) 222-5112.

Care Access opened its Memphis location in collaboration with local community leaders and healthcare providers seeking to make clinical research more accessible to local residents.

BOSTON — (BUSINESS WIRE) - A global research study is now available in Tamarac, Fla., for an investigational treatment to help patients with a history of atrial fibrillation (AFib) decrease their risk of stroke. Patients with AFib are known to have a four to five times higher risk of stroke than the general population. Anticoagulant treatments are regularly prescribed by physicians and proven to effectively reduce the incidence of strokes. However, data from multiple registries and claims-based data analyses have shown that anywhere from 40% to 60% of AFib patients are not being optimally treated today. This is especially true in older adults, those with kidney or liver disease, those needing concomitant antiplatelet therapy, and patients with other factors associated with an increased risk of bleeding.

The LILAC-TIMI 76 phase 3 study is currently enrolling for patients to evaluate the efficacy and safety of abelacimab in high-risk patients with AFib deemed unsuitable for current anticoagulants by their physicians. Abelacimab is a dual-acting Factor XI inhibitor that may offer a safer treatment option. By doing so, the hope is that the current treatment gap is closed so that more eligible patients can get the treatment they deserve.

“This study is particularly important for our community because the prevalence of AFib in South Florida is higher than the national average,” said Dr. Brad Lipson, Principal Investigator for Care Access - Tamarac. “It will provide valuable data that can be used to improve the prevention, diagnosis, and management of AFib. I encourage all eligible residents of Miami-Dade, Broward, and Palm Beach counties to participate in this important research.”

This research study is currently enrolling for adults ages 65+ with AFib, at high risk of stroke, and currently not taking certain oral anticoagulants or having stopped taking them within the last three months. To learn more, visit careaccess.com/studies or contact Care Access at (351) 222-5112.

Care Access opened its Tamarac location in collaboration with local community leaders and healthcare providers seeking to make clinical research more accessible to South Florida residents.